- Tiziana Life Sciences has announced the acquisition of an exclusive world-wide license for NI-1201, a fully human anti-interleukin-6 receptor (IL-6R) monoclonal antibody (mAb), from Novimmune SA.

In exchange for the exclusive license from Novimmune the Company agreed to an upfront cash payment, milestone payments, and a royalty on future sales.

Monoclonal antibodies against IL-6R have been explored as potential drugs to treat inflammation in the past.

NI-1201's unique mechanism, however, has the potential to considerably increase anti-inflammatory activity as well as complementing the Company's programme on foralumab (NI-0401), a fully human oral anti-CD3 mAb.

At 9:13am: [LON:TILS] Tiziana Life Sciences Plc Ord 3p share price was 0p at 192.5p

Story provided by